Literature DB >> 9783709

Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family.

S Verhoef1, C T Schrander-Stumpel, V D Vuzevski, A Tempelaars, L A Jansen, G A Malfeyt, T L Ceelen, D Lindhout, D J Halley, A M van den Ouweland.   

Abstract

A large Dutch family had been known for many years to be affected with skin tumours labelled as adenoma sebaceum, which were inherited in an autosomal dominant fashion. Since this skin sign is considered pathognomonic for tuberous sclerosis complex, the condition in the family was labelled accordingly, in the absence of further clinical features of tuberous sclerosis complex-like mental retardation or epilepsy. The skin changes started at early puberty with small eruptions around the nose and progressed to larger tumours, with considerable variation in severity. Some affected members had required plastic surgical reconstruction following excision. Linkage analysis in this family was performed for the two chromosomal regions involved in tuberous sclerosis complex on chromosomes 9q34 and 16p13, but no positive linkage was found. On critical re-evaluation of the clinical and pathological data and renewed assessment, the working diagnosis was changed to autosomal dominant cylindromatosis. The recently published candidate region for cylindromatosis on chromosome 16q12-13 was subsequently proven to be positively linked with a lod score of 3.02 with marker D16S308. Review of pathological specimens confirmed the diagnosis of cylindromatosis. DNA analysis of tumour tissue showed loss of heterozygosity for the cylindromatosis CYLD1 locus. These results confirm the candidate locus for cylindromatosis on chromosome 16q12-13.

Entities:  

Mesh:

Year:  1998        PMID: 9783709      PMCID: PMC1051461          DOI: 10.1136/jmg.35.10.841

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  7 in total

1.  Abnormal gene expressions of stroma cells in patients with tuberous sclerosis.

Authors:  Y Ishibashi; R Watanabe; T Nogita; T Takahashi; K Onodera; G Kimura
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Tuberous sclerosis. Special reference to the microscopic alterations in the cutaneous hamartomas.

Authors:  W R NICKEL; W B REED
Journal:  Arch Dermatol       Date:  1962-02

Review 3.  Dermal eccrine cylindromatosis.

Authors:  I D van Balkom; R C Hennekam
Journal:  J Med Genet       Date:  1994-04       Impact factor: 6.318

4.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

Authors:  M van Slegtenhorst; R de Hoogt; C Hermans; M Nellist; B Janssen; S Verhoef; D Lindhout; A van den Ouweland; D Halley; J Young; M Burley; S Jeremiah; K Woodward; J Nahmias; M Fox; R Ekong; J Osborne; J Wolfe; S Povey; R G Snell; J P Cheadle; A C Jones; M Tachataki; D Ravine; J R Sampson; M P Reeve; P Richardson; F Wilmer; C Munro; T L Hawkins; T Sepp; J B Ali; S Ward; A J Green; J R Yates; J Kwiatkowska; E P Henske; M P Short; J H Haines; S Jozwiak; D J Kwiatkowski
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas.

Authors:  P J Biggs; P Chapman; S R Lakhani; J Burn; M R Stratton
Journal:  Oncogene       Date:  1996-03-21       Impact factor: 9.867

6.  Familial cutaneous cylindromas: investigations in five generations of a family.

Authors:  A L Gerretsen; F A Beemer; W Deenstra; F A Hennekam; W A van Vloten
Journal:  J Am Acad Dermatol       Date:  1995-08       Impact factor: 11.527

7.  Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene.

Authors:  P J Biggs; R Wooster; D Ford; P Chapman; J Mangion; Y Quirk; D F Easton; J Burn; M R Stratton
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

  7 in total
  5 in total

1.  Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours.

Authors:  N Leonard; R Chaggar; C Jones; M Takahashi; A Nikitopoulou; S R Lakhani
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

2.  Analysis of loss of heterozygosity in Korean patients with keratoacanthoma.

Authors:  Tae-Won Ha; Ki-Hwan Han; Dae-Gu Son; Sang-Pyo Kim; Dae-Kwang Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

3.  Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1.

Authors:  M Nilsson; A B Undèn; D Krause; U Malmqwist; K Raza; P G Zaphiropoulos; R Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

4.  The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

Authors:  Alexandre Regamey; Daniel Hohl; Jia Wei Liu; Thierry Roger; Priit Kogerman; Rune Toftgard; Marcel Huber
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

5.  Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD.

Authors:  Nadine Hövelmeyer; F Thomas Wunderlich; Ramin Massoumi; Charlotte G Jakobsen; Jian Song; Marcus A Wörns; Carsten Merkwirth; Andrew Kovalenko; Monique Aumailley; Dennis Strand; Jens C Brüning; Peter R Galle; David Wallach; Reinhard Fässler; Ari Waisman
Journal:  J Exp Med       Date:  2007-10-08       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.